<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952168</url>
  </required_header>
  <id_info>
    <org_study_id>TJHCC-ACLC</org_study_id>
    <nct_id>NCT04952168</nct_id>
  </id_info>
  <brief_title>Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC</brief_title>
  <official_title>A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuan Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Prospective, open, single arm study to evaluate the efficacy and safety of the&#xD;
      almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with&#xD;
      EGFR mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">June 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year overall survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>The 2-year overall survival rate was defined as the rate of death within 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>From the first treatment to the date of first documentation of disease progression, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the first administration to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>NSCLC, Stage III</condition>
  <arm_group>
    <arm_group_label>Almonertinib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Almonertinib</intervention_name>
    <description>All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.</description>
    <arm_group_label>Almonertinib group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18, male or female.&#xD;
&#xD;
          2. Patients must provide written informed consent to participate in the study.&#xD;
&#xD;
          3. Patients must have biopsy proven unresectable stage III NSCLC (AJCC 8th).&#xD;
&#xD;
          4. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R).&#xD;
&#xD;
          5. Patients receiving almonertinib for 3 months and achieved stable disease, partial&#xD;
             response or completely response.&#xD;
&#xD;
          6. ECOG score 0-1&#xD;
&#xD;
          7. Demonstrate adequate organ function Patients evaluated as Cr, PR and SD were given&#xD;
             concurrent chemoradiotherapy 3 months after targeted therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients progress in 3 months after almonertinib treatment&#xD;
&#xD;
          2. Patient can't tolerate radiotherapy or targeted therapy&#xD;
&#xD;
          3. Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuan Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yuan Chen, MD</last_name>
    <phone>00862783663407</phone>
    <email>chenyuan008@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ping Peng, PhD</last_name>
    <phone>00862783663407</phone>
    <email>pengpingtj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ping Peng, PhD</last_name>
      <phone>13429818576</phone>
      <email>pengpingtj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Yuan Chen</investigator_full_name>
    <investigator_title>Head of chest oncology, Professor</investigator_title>
  </responsible_party>
  <keyword>Almonertinib</keyword>
  <keyword>chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

